Epithalon + Thymalin Anti-Aging Research Stack
Khavinson-protocol stack — pineal (Epithalon) + thymic (Thymalin) bioregulators for longevity and immune-senescence research.
The Epithalon + Thymalin combination represents the cornerstone of a research tradition stretching back more than four decades — one rooted not in Western academic medicine but in the Soviet and post-Soviet gerontology programmes based in Leningrad and, later, St Petersburg. Professor Vladimir Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology systematically isolated and characterised short peptide sequences — termed cytomins and cytogens — that appear to normalise tissue function in aged organisms. Epithalon (Ala-Glu-Asp-Gly), a synthetic tetrapeptide analogue of Epithalamin, targets the pineal gland. Thymalin, a polypeptide complex extracted from bovine thymus, targets the immune system's central training ground. Together they are designed to address two of the most consistent biomarkers of biological ageing: declining melatonin output and progressive thymic involution. Both compounds are unapproved research substances in the UK; this page summarises in vitro and animal-model findings only.
Why pair Epithalon with Thymalin?
Biological ageing is not governed by a single clock. Two of its most reproducible downstream consequences are the degradation of the pineal–circadian axis — manifesting as reduced nocturnal melatonin secretion and progressive circadian desynchronisation — and the regression of the thymus, which begins in early adulthood and leaves the adaptive immune system increasingly dependent on a contracting pool of long-lived T-cell clones. These two processes are not independent: melatonin receptors are expressed on thymocytes, and experimental pinealectomy in rodents accelerates thymic atrophy and T-cell senescence.
Epithalon addresses the upstream, pineal side of the axis; Thymalin addresses the downstream, immune side. Khavinson's group described this as a "bioregulator tandem" in which each peptide reinforces the other's geroprotective signal. In long-running rodent cohort studies where both compounds were administered together — rather than sequentially — the combination produced longevity and immune-restoration findings that exceeded either compound administered alone. The biological logic for co-administration is therefore stronger here than in many peptide combinations based purely on empirical observation.
Mechanism of action — each peptide
Epithalon — mechanism of action
Epithalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide whose structure mirrors the active fragment of Epithalamin, a polypeptide extract of the bovine pineal gland characterised by Khavinson and colleagues in the 1970s and 1980s. Its principal documented actions in animal and cell-culture studies are:
- Telomerase activation — In a landmark 2003 paper (Khavinson et al., PMID: 12910687), Epithalon was shown to up-regulate telomerase activity in human somatic cell cultures and to produce measurable telomere elongation in cells that had entered a pre-senescent state. This is one of the few instances in which a short synthetic peptide has been reported to reactivate the enzyme in non-tumour cells.
- Pineal melatonin normalisation — Epithalon stimulates synthesis and secretion of melatonin by pinealocytes in aged animal models where baseline secretion is suppressed. The mechanism is thought to involve direct interaction with the pineal transcription machinery rather than receptor-mediated stimulation, though this is not fully resolved.
- Circadian rhythm restoration — In elderly human subjects administered Epithalamin (the natural analogue), Korkushko et al. documented restoration of nocturnal melatonin amplitude and phase toward the profiles observed in younger subjects [PMID: 21259072].
- Anti-tumour effects — In transgenic HER-2/neu mice, Epithalon reduced spontaneous mammary tumour incidence and promoted neoplastic-cell differentiation, an effect attributed in part to restored immune surveillance [PMID: 12932673].
- Chromatin remodelling — Epithalon has been reported to activate condensed chromatin in senescent human fibroblasts, potentially restoring access to silenced genes [PMID: 14514995].
In research protocols, Epithalon is typically dosed in the evening to align with the natural circadian peak of pineal activity.
Thymalin — mechanism of action
Thymalin is a polypeptide fraction extracted and purified from bovine thymic tissue. Unlike the fully synthetic Epithalon, Thymalin is a heterogeneous mixture of low-molecular-weight thymic peptides; its characterisation was developed in parallel with Epithalamin by Khavinson and Morozov from the 1970s onward. Its documented mechanisms in published research include:
- T-cell maturation and repertoire restoration — Thymalin acts on thymic stromal cells and on circulating pre-T-lymphocytes to support the maturation pathway that is progressively impaired by age-related thymic involution. In aged rodent models, administration restores CD4/CD8 ratio and naive T-cell proportions toward values observed in younger animals.
- Natural killer (NK) cell activity — Thymalin has been shown to increase NK-cell cytotoxic activity in animal models, a function that is critical to immune surveillance against nascent tumour cells and is consistently depressed in aged immune systems.
- Cytokine balance normalisation — Animal-model studies have documented reduction of chronically elevated pro-inflammatory cytokines (IL-6, TNF-α) and restoration of IL-2 and IFN-γ production — a shift consistent with reversal of the "inflammageing" phenotype.
- Thymopoietin-like signalling — Thymalin contains peptide fractions with structural homology to thymopoietin and thymulin, established thymic hormones that decline steeply with age. This structural similarity is the molecular rationale for its immune-restorative properties.
Thymalin is administered in the morning in published research protocols, allowing its immune-modulatory signal to operate during the period of peak lymphocyte trafficking.
Summarised studies on the combination
The most extensive published body of evidence for the Epithalon + Thymalin combination emerges from the long-running rodent longevity cohorts conducted by Vladimir Khavinson's group and the parallel carcinogenesis-and-ageing programme led by Vladimir Anisimov at the N.N. Petrov Research Institute of Oncology in St Petersburg.
Rodent lifespan cohorts (Anisimov, Khavinson et al., 1982–2003) — In a foundational series of experiments using C3H/Sn mice, administration of thymic and pineal polypeptide preparations — the natural precursors of Thymalin and Epithalon — over the course of animals' lifetimes produced mean lifespan extensions of approximately 10–25% compared to untreated controls [PMID: 7121995]. Tumour incidence was also reduced. The combination produced superior outcomes compared to either preparation administered alone, consistent with the complementary-axis hypothesis described above.
Swiss-derived SHR mice (Anisimov et al., 2003) — A formal evaluation of Epithalon administered on the short-course protocol (10 consecutive days, repeated periodically) in female SHR mice reported a 12.3% increase in mean lifespan alongside a statistically significant reduction in spontaneous tumour incidence [PMID: 12766536]. This study is notable for its use of the episodic short-course protocol that subsequently became the standard in Khavinson-group research — mimicking the biannual course design used in the human pilot data.
Human observational data (Korkushko et al., 2011) — A 15-year follow-up of elderly subjects who received Epithalamin (the natural polypeptide analogue) on a biannual course protocol reported a 1.6- to 1.8-fold lower mortality rate relative to the untreated cohort, with improvements in cardiovascular and immune biomarkers sustained across the observation window [PMID: 22268128]. While this is not a randomised controlled trial, its duration is exceptional in the peptide-bioregulator literature and represents the most longitudinal human dataset available.
Telomerase reactivation (Khavinson et al., 2003) — The demonstration that Epithalon activates telomerase in pre-senescent human somatic cells [PMID: 12910687] provided a plausible molecular mechanism for its geroprotective effects beyond immunomodulation, and remains the most-cited single paper in the Epithalon literature.
No registered human clinical trials have evaluated Epithalon or Thymalin as a formal pharmaceutical intervention. All combination efficacy data is preclinical or from non-randomised observational series.
Full research protocol
The protocol below reflects the short-course design most consistently applied across Khavinson-group publications — a 10-consecutive-day course administered twice yearly, here presented as a three-week MDX unit to capture the lead-in, course, and rest observation window.
| Peptide | Dose | Frequency | Timing | Cycle length |
|---|---|---|---|---|
| Epithalon | 10 mg | Daily SC | Evening | 10 days |
| Thymalin | 10 mg | Daily SC | Morning | 10 days |
Daily research timeline
| Peptide | Wk 1 | Wk 2 | Wk 3 |
|---|---|---|---|
| Epithalon | 10 mg/d | 10 mg/d | — |
| Thymalin | 10 mg/d | 10 mg/d | — |
- Days 1–10 (weeks 1–2, active phase): Both peptides are administered daily. Epithalon is dosed subcutaneously in the evening to align with the circadian profile of pineal activity. Thymalin is dosed subcutaneously in the morning to align with peak lymphocyte trafficking. The two injections are administered at separate sites.
- Days 11–21 (week 3, observation window): No active dosing. Published protocols document this rest window before repeat assessment of biomarkers; in the biannual model, the next course begins at approximately six months.
- Repeat cycle: Khavinson-group publications describe two courses per year as the standard research interval. The interval is empirically derived from observed durability of melatonin and immune-biomarker improvements in rodent and human observational data.
Reconstitution & storage notes
Both Epithalon and Thymalin are supplied as lyophilised powder and should be reconstituted using bacteriostatic water for injection. Epithalon at 10 mg reconstitutes cleanly in 1 mL bacteriostatic water to give a 10 mg/mL working solution; this concentration is stable at 2–8 °C for approximately 30 days. Thymalin is a polypeptide mixture and is similarly reconstituted at 10 mg/mL; it is somewhat more sensitive to temperature fluctuation and should be stored at 2–8 °C immediately after reconstitution. Neither compound should be subjected to repeated freeze-thaw cycles: prepare single-use aliquots before any extended frozen storage. Both peptides are light-sensitive; amber or foil-wrapped vials are recommended.
Where to source these research peptides
Each peptide in this stack has a dedicated research monograph on PeptideAuthority.co.uk and a research-grade SKU at PeptideBarn.co.uk. All compounds are sold strictly for in vitro research.
Related research
Researchers investigating the pineal–thymic longevity axis may also be interested in the Epitalon + Humanin + MOTS-c Longevity Stack, which extends the mitochondrial and telomeric dimensions of the Epithalon protocol with two mitochondria-derived peptides, and the SS-31 + Humanin Mitochondrial Stack, which focuses specifically on mitochondrial membrane protection and bioenergetic restoration as complementary targets in the biology of ageing.
For full underlying monographs on each compound, see the per-peptide profiles at PeptideAuthority.co.uk/peptides/epitalon and PeptideAuthority.co.uk/peptides/thymalin.
Frequently asked research questions
References
Peer-reviewed sources for the claims summarised above. Links open PubMed or the journal DOI.
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003 doi:10.1023/A:1025493705728 · PMID: 12910687
- Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pineal gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bulletin of Experimental Biology and Medicine. 2011 doi:10.1007/s10517-011-1270-x · PMID: 22268128
- Anisimov VN, Khavinson VKh, Morozov VG. Carcinogenesis and aging. Effect of low-molecular-weight factors of thymus, pineal gland and anterior hypothalamus on immunity, tumor incidence and life span of C3H/Sn mice. Mechanisms of Ageing and Development. 1982 doi:10.1016/0047-6374(82)90023-1 · PMID: 7121995
- Anisimov VN, Khavinson VKh, Popovich IG, et al.. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003 doi:10.1023/A:1023907525849 · PMID: 12766536
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters. 2003 · PMID: 12967738
- Korkushko OV, Shatilo VB, Khavinson VKh, Antonyk-Sheglova IA. Effect of the pineal tetrapeptide Epithalamin on circadian rhythms of melatonin secretion and body temperature in elderly subjects. Bulletin of Experimental Biology and Medicine. 2010 doi:10.1007/s10517-010-1083-5 · PMID: 21259072
- Anisimov VN, Khavinson VKh, Alimova IN, et al.. Epithalon inhibits spontaneous carcinogenesis and promotes differentiation of neoplastic cells in mammary gland in transgenic HER-2/neu mice. European Journal of Cancer. 2003 doi:10.1016/S0959-8049(03)00412-5 · PMID: 12932673
- Khavinson VKh, Lezhava TA, Jokhadze TA, et al.. Peptide Epitalon activates chromatin in cells of human fibroblasts. Neuro Endocrinology Letters. 2003 · PMID: 14514995
Related longevity & anti-aging stacks
Epitalon + Humanin + MOTS-c Longevity Stack — Research Protocol
Three-peptide longevity research stack targeting telomerase activation, mitochondrial unfolded-protein response and metabolic ageing. Full dosing protocol and UK regulatory note.
SS-31 + Humanin Mitochondrial Research Stack
Mitochondrial-targeted research stack — SS-31 (Elamipretide) and Humanin. Cardiolipin stabilisation and mitochondrial unfolded protein response (MUPR).